Achelios Therapeutics develops patented topical formulations that dramatically increase skin permeation of NSAIDs, enabling high‑dose delivery of anti‑inflammatory drugs directly to joints, facial tissues, and migraine sites.
Funding
$350K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with chronic joint, temporomandibular, and migraine pain often rely on oral NSAIDs, which can cause systemic side effects and provide limited localized relief. Existing topical formulations fail to deliver sufficient drug quantities through the skin to reach the target tissues, leaving an unmet need for effective, site‑specific anti‑inflammatory therapy.
Solution
Achelios Therapeutics creates “New Therapeutic Entities” (NTE) that combine existing NSAIDs with a patented formulation designed to enhance dermal permeation in a compound‑selective manner. The technology enables high concentrations of NSAIDs to cross human skin and accumulate in the underlying joint or facial tissues, providing localized anti‑inflammatory and analgesic effects while minimizing systemic exposure. By reformulating known drugs, Achelios can rapidly advance candidates into clinical development for conditions such as arthritis, temporomandibular joint disorder, and migraine‑related facial pain. The approach focuses on delivering topical medications that achieve therapeutic levels at the site of pain, offering patients a non‑steroidal alternative to oral therapy.
Target Audience
Primary customers are pharmaceutical companies and biotech firms developing pain‑relief products, as well as clinicians seeking topical therapies for patients with chronic joint, TMJ, or migraine‑related facial pain.
Features
- Patented formulation that selectively increases skin permeation of large‑molecule NSAIDs
- Enables delivery of therapeutically relevant drug concentrations to deep joint and facial tissues
- Utilizes repurposed, clinically validated NSAIDs to accelerate development timelines
- Designed for topical application, reducing systemic absorption and associated adverse events
- Targets chronic inflammatory pain conditions with high unmet medical need